Quantum BioPharma Growth Summit

Quantum BioPharma Will Showcase Lead MS Drug at Toronto Growth Summit

Quantum BioPharma Ltd. (NASDAQ: QNTM) is set to participate in the 3rd Annual ArcStone-Kingswood Growth Summit 2026 in Toronto. The company will present at the Sheraton Center Toronto Hotel with Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharm. The ArcStone Growth Summit will host growth issuers and a curated group of investors, family offices, institutional investors, and service providers for a full day of company presentations, networking, and 1-on-1 meetings. Quantum BioParma's lead compound, Lucid-MS, is designed to provide neuroprotection through the inhibition of demyelination, a key contributor to disability progression in multiple sclerosis. Lucid MS represents a unique approach to address the underlying neurodegeneration, a novel mechanism to address this issue.